EP1351677A2 - Methode de traitement du cancer - Google Patents

Methode de traitement du cancer

Info

Publication number
EP1351677A2
EP1351677A2 EP02720788A EP02720788A EP1351677A2 EP 1351677 A2 EP1351677 A2 EP 1351677A2 EP 02720788 A EP02720788 A EP 02720788A EP 02720788 A EP02720788 A EP 02720788A EP 1351677 A2 EP1351677 A2 EP 1351677A2
Authority
EP
European Patent Office
Prior art keywords
administered
combination
administration
agents
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02720788A
Other languages
German (de)
English (en)
Other versions
EP1351677A4 (fr
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNumerik Pharmaceuticals Inc
Original Assignee
BioNumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNumerik Pharmaceuticals Inc filed Critical BioNumerik Pharmaceuticals Inc
Publication of EP1351677A2 publication Critical patent/EP1351677A2/fr
Publication of EP1351677A4 publication Critical patent/EP1351677A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to a method for treating patients afflicted with cancer, and will have application to a combination drug treatment possessed of fewer and less severe unwanted toxic adverse effects.
  • Combination chemotherapy is a common, accepted treatment for many types of cancers.
  • the synergistic effects of combining two or more agents can be the difference between successful and unsuccessful treatment of the patient.
  • MOPP an acronym for mechlorethamine, vincristine, procarbazine, prednisone
  • MOPP an acronym for mechlorethamine, vincristine, procarbazine, prednisone
  • Several different combination regimens (which all include cisplatin, vinblastine and bleomycin) are accepted in the treatment of testicular cancer, which is curable in up to 98% of diagnosed cases. In all, more than 300 different combination regimens have been used.
  • paclitaxel Another consideration of importance in combination chemotherapy is the order in which the antineoplastic agents are administered. For instance, where cisplatin, or carboplatin (or any platinum complex antineoplastic agent) and paclitaxel are administered as a part of a combination treatment regimen, it has been shown that due to toxicity considerations, paclitaxel must be administered first, followed by administration of cisplatin. If the order of administration is reversed, the combination is highly toxic to the patient. The manifestation of such severe schedule dependent toxicity precludes the administration of the cisplatin followed by paclitaxel combination because of the risk of serious toxicities, morbidity and even death.
  • Disodium 2 , 2' -dithiobis ethane sulfonate (also referred to in the literature as Dimesna and BNP7787) has been shown to reduce the unwanted toxic effects associated with the administration of single agent cisplatin, and of single agent paclitaxel in human patients.
  • Dimesna is generally regarded as extremely safe and efficacious for these uses and others, and has been shown not to interfere with the cytotoxic effects of the antineoplastic agent (s) with which it is co-administered.
  • This invention relates to methods of treating patients with cancer by administering combination chemotherapy wherein effective amounts and schedules of administration of two or more antineoplastic agents are administered to the patient, together with a toxicity reducing amount of a protective agent of the following formula I : (I)
  • RT is hydrogen, Ci-C ⁇ alkyl, or -S-X 2 -R 3 ; R 2 and R 3 are each individually sulfonate or phosphonate; and Xi and X 2 are each individually Ci-C ⁇ alkyl, optionally substituted by one or more hydroxy, sulfhydryl or alkoxy moieties .
  • Preferred antineoplastic agents include platinum based chemotherapy drugs (cisplatin, carboplatin, oxaliplatin, and others) and taxanes (including, but not limited to paclitaxel, docetaxel), and/or epothilones, and or vinca alkaloids, and/or oxazaphosphorines or other agents used in the chemotherapy of cancer, though the method of this invention is contemplated as useful in any of a vast number of combination chemotherapy regimens.
  • platinum based chemotherapy drugs cisplatin, carboplatin, oxaliplatin, and others
  • taxanes including, but not limited to paclitaxel, docetaxel
  • epothilones include vinca alkaloids, and/or oxazaphosphorines or other agents used in the chemotherapy of cancer, though the method of this invention is contemplated as useful in any of a vast number of combination chemotherapy regimens.
  • Another object of this invention is to provide a new method of treating patients with cancer through combination chemotherapy along with a toxicity-preventing agent.
  • Another object is to provide for novel, safer, more effective methods of treating patients with cancer.
  • combination chemotherapy involves administering two or more different antineoplastic agents using a schedule of administration to the patient that results in reduced toxicity and increased antitumor efficacy as a result of the administration of a toxicity reducing agent.
  • the method of this invention specifically includes in addition to the antineoplastic agents, the administration of a toxicity- reducing amount of a protective agent of formula I:
  • Ri is hydrogen, Ci-C ⁇ alkyl, or -S-X 2 -R 3 ; R 2 and R 3 are each individually sulfonate or phosphonate; and
  • X ⁇ and X 2 are each individually Ci-C ⁇ alkyl, optionally substituted by one or more hydroxy, sulfhydryl or alkoxy moieties.
  • the preferred protective agents of formula I include various thiols, disulfides and thioethers .
  • Some preferred compounds of formula I include, but are not limited to mesna, dimesna, S-methyl mesna, and various analogues and derivatives of each wherein the alkylene bridge (s) include one to four -CH 2 - moieties, and may or may not be substituted by hydroxy or alkoxy moieties.
  • Most preferred compounds of formula I include mesna and dimesna.
  • antineoplastic agents include combinations of taxanes and platinum complex agents; electrophilic alkylating agents and vinca alkaloids, oxazaphosphorines, platinum and vinca alkaloids or bleomycin, with or without steroidal antineoplastic compounds; platinum complexes and vinca alkaloids, with or without antineoplastic antibiotics; and others, some of which are shown in the following tables .
  • the dose, the duration of drug infusion, the route of administration, and the order of administration of the antineoplastic agents can determine the outcome of treatment and to significantly affect the toxicity, drug related morbidity and death of a patient due to drug treatment.
  • the timing between doses and the duration of infusion of each agent has an effect on the safety and the efficacy outcome of treatment.
  • the current protocol for paclitaxel/cisplatin combination therapy calls for each cycle of treatment to involve the administration of paclitaxel from 3 hours to 96 hours of the drug followed by the administration of cisplatin. Each cycle is repeated at approximately 3-week intervals.
  • Administration of toxicity reducing amounts and novel schedules of administration of a formula I compound in conjunction with the administration of the combination of antineoplastic agents is postulated to improve the antitumor efficacy and safety throughout the course of treatment of the patient.
  • adherence to the method of this invention may allow the physician to safely administer higher amounts of the antineoplastic agents, at shorter time intervals, thus improving the probability of success of a particular course of treatment.
  • a preferred course of treatment under the method of this invention is the administration of effective amounts of a taxane/platinum combination, in conjunction with a formula I compound.
  • the preferred course for platinum followed by taxanes includes the administration, every 1-21 days of: a) 10 mg/m 2 -300 mg/m 2 of a platinum drug over 15 minutes to 96 hours, followed by the administration of b) 10 mg/m 2 -400 mg/m 2 of a taxane; administered over 15 minutes to 96 hours; and c) 2 g/m 2 -50 g/m 2 of a compound of formula I that is administered over 15 minutes to 96 hours preceding the platinum administration and the provisional administration of the formula I compound over 15 minutes to 96 hours as a single or divided dose before, during or after the administration of the taxane.
  • the preferred course of treatment includes the IV infusion of first, a formula I compound, followed by IV infusion of the platinum drug, followed by the administration of the taxane.
  • This is an entirely novel schedule of platinum and taxane administration in combination with a toxicity reducing agent.
  • conventional pre-medication for nausea and vomiting may be administered as per accepted medical practices .
  • Cisplatin is preferably administered by IV infusion over an extended period, generally from 1-12 hours, most preferably from 1-4 hours
  • Dimesna may be administered by IV push or infusion, or may be administered orally, and is preferably administered immediately or up to 90 minutes prior to the commencement of the IV cisplatin infusion.
  • the duration of the dimesna infusion can be from 15 minutes to continuous infusion for as long as needed to prevent toxicity.
  • a patient suffering from cancer is treated as follows : a) 4 g/m 2 -80 g/m 2 of dimesna is administered either by intravenous infusion over 15-90 minutes, or by oral administration route; b) within one hour of completion of a) 15 mg/m 2 -250 mg/m 2 of a platinum complex agent is administered either by intravenous infusion at a rate of 0.5 mg/min-2 mg/min; c) within 2 hours of completion of b) 20 mg/m 2 -250 mg/m 2 of a taxane agent is administered by either intravenous infusion over 15 minutes-96 hours, or by oral administration route.
  • a patient suffering from cancer is treated as follows: a) 4 g/m 2 -80 g/m 2 of dimesna is administered either by intravenous infusion over 15-90 minutes, or by oral administration route; b) within one hour of completion of a) 15 mg/m 2 -250 mg/m 2 of a platinum complex agent is administered either by intravenous infusion at a rate of 0.5 mg/min-2 mg/min; c) within one hour of completion of b) 4 g/m 2 -80 g/m 2 of dimesna is again administered either by intravenous infusion over 15-90 minutes, or by oral administration route; d) within 2 hours of completion of c) 20 mg/m 2 -250 mg/m 2 of a taxane agent is administered by either intravenous infusion over 15 minutes-96 hours, or by oral administration route.
  • a patient suffering from cancer is treated as follows: a) 4 g/m 2 -80 g/m 2 of dimesna is administered either by intravenous infusion over 15-90 minutes, or by oral administration route; b) within one hour of completion of a) 15 mg/m 2 -250 mg/m 2 of a platinum complex agent is administered either by intravenous infusion at a rate of 0.5 mg/min-2 mg/min; c) within 24 hours of completion of b) 4 g/m 2 -80 g/m 2 of dimesna is again administered either by intravenous infusion over 15-90 minutes, or by oral administration route; d) within 2 hours of completion of c) 20 mg/m 2 -250 mg/m 2 of a taxane agent is administered by either intravenous infusion over 15 minutes-96 hours, or by oral administration route; e) within 2 hours of completion of d) 4 g/m 2 -80 g/m 2 of dimesna is again administered either by intravenous infusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode de traitement de patients souffrant de cancer, qui consiste à administrer un schéma posologique combiné d'un agent au platine, d'un agent au taxane et d'un agent réduisant la toxicité, de formule (I). L'ordre d'administration préféré est le suivant : composé de formule I, complexe platine et agent au taxane.
EP02720788A 2001-01-19 2002-01-11 Methode de traitement du cancer Withdrawn EP1351677A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26312701P 2001-01-19 2001-01-19
US263127P 2001-01-19
PCT/US2002/000943 WO2002056755A2 (fr) 2001-01-19 2002-01-11 Methode de traitement du cancer a effacite superieure et effets indesirables reduits

Publications (2)

Publication Number Publication Date
EP1351677A2 true EP1351677A2 (fr) 2003-10-15
EP1351677A4 EP1351677A4 (fr) 2009-08-19

Family

ID=23000486

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02720788A Withdrawn EP1351677A4 (fr) 2001-01-19 2002-01-11 Methode de traitement du cancer

Country Status (6)

Country Link
EP (1) EP1351677A4 (fr)
JP (2) JP2004523518A (fr)
AU (1) AU2002251763B2 (fr)
CA (1) CA2434270A1 (fr)
MX (1) MXPA03006359A (fr)
WO (1) WO2002056755A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
AU2008352597B2 (en) * 2008-03-14 2012-03-08 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
JP5667886B2 (ja) * 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
CA2717915A1 (fr) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Procedes et compositions pour la chimioprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
PT957920E (pt) * 1996-09-23 2002-06-28 Bionumerik Pharmaceuticals Inc Reducao dos efeitos toxicos de carboplatina utilizando ditioeteres

Also Published As

Publication number Publication date
JP2009292837A (ja) 2009-12-17
CA2434270A1 (fr) 2002-07-25
MXPA03006359A (es) 2004-04-20
WO2002056755A3 (fr) 2002-09-26
WO2002056755A2 (fr) 2002-07-25
AU2002251763B2 (en) 2006-05-04
EP1351677A4 (fr) 2009-08-19
JP2004523518A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
BG107843A (bg) Ефективно антитуморно лечение
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
RU2391101C2 (ru) Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
HK1045462B (zh) 含吗啉蒽环类衍生物和抗癌剂的联合制剂
Abou-Jawde et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial
EP1014990B1 (fr) Combinaison antitumorale de 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
US6596320B1 (en) Method for treating cancer having greater efficacy and reduced adverse effects
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法
AU4325493A (en) Glutathione as chemoprotective agent
JP2007511509A (ja) Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
AU2002251763A1 (en) Method for treating cancer
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
US6939893B2 (en) Method of reducing toxicity of anticancer agents
EP1273296B1 (fr) Combinaison de l'acetyldinaline et de docetaxel
EP1734972A4 (fr) Procede pour traiter des tumeurs solides et des leucemies au moyen d'une therapie combinatoire de vitamine d et d'analogues de nucleosides anti-metabolisme
KR20010102402A (ko) 상승작용성 항종양 조성물
MX2011006253A (es) Combinacion antitumoral que asocia ave8062 y docetaxel.
WO2008033039A1 (fr) Traitement du cancer
HK1096538A (en) Combined preparations comprising anthracycline derivatives
HK1068786A (en) Combined preparations comprising anthracycline derivatives
HK1096867A (en) Combined preparations comprising anthracycline derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030707

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20090707BHEP

Ipc: A61K 31/185 20060101ALI20090707BHEP

Ipc: A61K 31/663 20060101ALI20090707BHEP

Ipc: A61K 33/24 20060101ALI20090707BHEP

Ipc: A61K 31/105 20060101ALI20090707BHEP

Ipc: A61K 31/335 20060101AFI20030716BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090716

17Q First examination report despatched

Effective date: 20100324

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIONUMERIK PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160317